Zydus Lifesciences Ltd and Germany-based Formycon AG have received acceptance from the US Food and Drug Administration (USFDA) for review of their biologics licence application (BLA) for FYB206, a proposed biosimilar to Keytruda (pembrolizumab), the world’s bestselling biologic medicine. The companies said the acceptance, following the application’s submission in the third quarter of 2026, was […]